Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 11:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 1,459 matching trials from the live ClinicalTrials.gov search.
Completed Phase 3 Interventional Results available

Behavioral Treatment of Overactive Bladder in Men

NCT01187498
Conditions
Overactive Bladder
Interventions
Behavioral training, Oxybutynin chloride, extended-release
Behavioral · Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
19 Years and older · Male only
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Birmingham, Alabama • Decatur, Georgia
Conditions
Overactive Bladder
Interventions
hMaxi-K, Placebo
Drug · Other
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Branford, Connecticut
Recruiting Early Phase 1 Interventional

NSAIDs Stent Study

NCT03638999
Conditions
Ureteral Stent Placement, Kidney Stone
Interventions
Ketorolac Trometamol 30Mg/1mL Injection, Normal saline
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Colorectal Cancer, Bladder Cancer, Ovarian Cancer, Cervical Cancer, Uterine Cancer
Interventions
Patient-Reported Outcomes-Informed Symptom Management System (PRISMS)
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Stress Urinary Incontinence
Interventions
Duloxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Vaginal Prolapse
Interventions
AMS Prolapse Product
Device
Lead sponsor
ASTORA Women's Health
Industry
Eligibility
21 Years and older · Female only
Enrollment
1,543 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Whitinsville, Massachusetts
Completed Phase 4 Interventional Results available

Deprescribing Tamsulosin in Older Men

NCT05415748
Conditions
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Interventions
Tamsulosin, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
55 Years to 80 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Francisco, California
Conditions
Urinary Incontinence
Interventions
Athena Pelvic Muscle Trainer
Device
Lead sponsor
Athena Feminine Technologies, Inc.
Industry
Eligibility
30 Years to 70 Years · Female only
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
96
States / cities
Birmingham, Alabama • Dothan, Alabama • Casa Grande, Arizona + 87 more
Conditions
Stone;Renal, Stone, Kidney, Stone Ureter
Interventions
Not listed
Lead sponsor
Société Internationale d'Urologie
Other
Eligibility
18 Years to 99 Years
Enrollment
2,348 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Accuracy of Ultrasound for Detecting Residual Fragments During RIRS

NCT05535816
Conditions
Stone, Kidney, Ultrasound Therapy; Complications
Interventions
Ultrasound
Diagnostic Test
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Francisco, California
Not listed Not applicable Interventional Accepts healthy volunteers

Does Spinal Anesthesia for Prolapse Surgery With Lead to Urinary Retention?

NCT02547155
Conditions
Urinary Retention, Uterine Prolapse
Interventions
Spinal anesthesia, General anesthesia
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
40 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Weston, Florida
Conditions
Kidney Stones
Interventions
Ureteroscopy using the 6.3 Fr f-URS hugemed, Hugemed 6.3 Fr f-URS
Device
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Urinary Incontinence, Detrusor Overactivity, Urinary Urgency, Urge Urinary Incontinence
Interventions
Botulinum Toxin A, bladder detrusor muscle injection, Vehicle saline as placebo
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
21 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
8
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 5 more
Conditions
Nocturia
Interventions
Desmopressin, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
10
States / cities
Aventura, Florida • DeLand, Florida • Peoria, Illinois + 6 more
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of a Prostate Health Formulation

NCT02886832
Conditions
Prostate Health
Interventions
Prostate Health formulation
Dietary Supplement
Lead sponsor
Supplement Formulators, Inc.
Industry
Eligibility
45 Years to 75 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Conditions
Obesity, Overactive Bladder, Incontinence
Interventions
Trospium Chloride, Extended Release (XR), placebo
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
La Mesa, California
Conditions
Urothelial Cancer, Metastatic Urothelial Cancer, Bladder Cancer, Bladder Cancer (BC), Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable, Bladder Ca, Bladder Cancer Recurrent, Bladder Cancer Stage IV, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent, Urothelial Carcinoma of the Urinary Bladder
Interventions
T-Bren, Dose level 1, T-bren, Dose level 2, Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin)
Drug
Lead sponsor
SystImmune Inc.
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Macon, Georgia • ‘Aiea, Hawaii • Fredericksburg, Virginia
Conditions
Urolithiasis, Stones, Kidney, Renal Stones, Kidney Stones
Interventions
Steerable Ureteroscopic Renal Evacuation (SURE) using the CVAC System, Standard Ureteroscopy (URS)
Device
Lead sponsor
Calyxo, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Birmingham, Alabama • Gainesville, Florida • New York, New York + 3 more
Completed No phase listed Observational Accepts healthy volunteers

A Study of Robotic Assisted Laparoscopic Sacral Colpopexy Using Alyte Mesh

NCT01320644
Conditions
Pelvic Organ Prolapse, Urinary Incontinence, Mesh Erosion
Interventions
Not listed
Lead sponsor
Atlantic Health System
Other
Eligibility
21 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Morristown, New Jersey
Conditions
Urinary Incontinence, Urinary Bladder, Overactive
Interventions
BOTOX®
Biological
Lead sponsor
Allergan
Industry
Eligibility
12 Years to 17 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
8
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Aurora, Colorado + 5 more
Conditions
Urinary Incontinence, Bladder Dysfunction
Interventions
Fesoterodine Oral Product
Drug
Lead sponsor
Saint Thomas Health
Other
Eligibility
21 Years to 85 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Prostatic Hyperplasia, Stress Urinary Incontinence
Interventions
Pelvic floor physical therapy
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Orange, California
Conditions
Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma, Erdheim-Chester Disease, Lip and Oral Cavity Carcinoma, Lymphangioleiomyomatosis, Malignant Endocrine Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Male Reproductive System Neoplasm, Malignant Neoplasm, Malignant Respiratory Tract Neoplasm, Malignant Thoracic Neoplasm, Malignant Urinary System Neoplasm, Mesothelial Neoplasm, Metastatic Malignant Neoplasm, Metastatic Urothelial Carcinoma, Neurofibromatosis Type 2, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Digestive System Carcinoma, Recurrent Female Reproductive System Carcinoma, Recurrent Male Reproductive System Carcinoma, Recurrent Malignant Neoplasm, Recurrent Pharyngeal Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Malignant Neoplasm, Soft Tissue Neoplasm, Stage III Breast Cancer AJCC v7, Stage III Pharyngeal Cancer, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Pharyngeal Cancer, Stage IVA Pharyngeal Cancer, Stage IVB Pharyngeal Cancer, Stage IVC Pharyngeal Cancer, Thyroid Gland Neoplasm
Interventions
Bevacizumab, Cetuximab, Laboratory Biomarker Analysis, Pharmacological Study, Temsirolimus, Valproic Acid
Biological · Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Urinary Bladder, Overactive
Interventions
Mirabegron, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
2,149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
109
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 100 more